- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01386294
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase III, multicenter trial to assess the safety and effectiveness of 1% tenofovir gel, administered vaginally by approximately 2900 sexually active women at high risk for sexually transmitted HIV. Approximately 2600 women aged 18-30 years old will be enrolled to achieve the required number of endpoints to show an effect on HIV-1 infection, while up to 300 additional women aged 31-40 years old will be enrolled to collect more safety information in this age group.
This is an event driven study that plans to randomize seronegative women. Participants will be randomized to a 1:1 ratio to receive 1% tenofovir gel or placebo gel. Each will be asked to insert a dose of the assigned study product within 12 hours prior to a coital event and another dose as soon as possible within 12 hours after a coital event. Participants will be advised to use only two doses of gel in a 24 hour period.
All women will be evaluated for the rates of adverse events and the rate of HIV seroconversion. In addition, the study will evaluate several secondary endpoints that bear directly on potential risks and benefits of vaginal tenofovir gel use.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Cape Town, South Africa
- Desmond Tutu HIV Centre / University of Cape Town
-
Diepkloof, South Africa
- Perinatal HIV Research Unit / University of the Witwatersrand
-
Hillbrow, South Africa
- Wits Reproductive Health and HIV Institute / University of the Witwatersrand
-
Ladysmith, South Africa, 3370
- Qhakaza Mbokodo Research Clinic
-
Pretoria, South Africa
- Medunsa Clinical Research Unit / Ga-Ra
-
Rustenburg, South Africa
- The Aurum Institute (Rustenburg)
-
Soshanguve, South Africa
- Setshaba Research Centre
-
Tembisa, South Africa
- The Aurum Institute, Tembisa Hospital
-
-
Kwa-Zulu NAtal
-
Pietermaritzburg, Kwa-Zulu NAtal, South Africa, 316
- MatCH Edendale Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed age 18-40 years (inclusive)
- Able and willing to provide written informed consent
- Able and willing to provide adequate locator information for study retention and safety purposes
- Sexually active, defined as having had vaginal intercourse at least twice in the past 30 days prior to screening
- HIV negative on two rapid tests performed by study staff within 30 days of enrolment (see algorithm in Appendix 3).
- No evidence of glycosuria
- No evidence of proteinuria greater than trace*
- No history of pathological bone fractures
- Have a negative pregnancy test
- Women currently breastfeeding may be enrolled in the study
- Agree to use a study-approved effective non-barrier form of contraception
- Agree to adhere to study visits and procedures
- Willing to use study gel as advised
Not using or taking any of the following groups of medications:
- Nephrotoxic agents
- Drugs that slow renal excretion
- Immune system modulators
- Other antiretrovirals
Exclusion Criteria:
- History of adverse reaction to latex.
Plans any of the following during the study period
- To travel away from the study site for more than 30 consecutive days.
- To relocate away from the study site.
- To become pregnant.
- To enrol in any other study of an investigational product or behaviour modification related to HIV prevention.
- If in the opinion of the examining clinician, is not sexually active
- Inadequate renal function (serum creatinine greater than 1.5mg/dl and creatinine clearance less than 50ml/min, as estimated using the method of Cockcroft and Gault96 )
- Grade 3 and above ALT and AST at screening or any clinical sign of liver disease ( e.g. ascites, hepatomegaly, jaundice)
- Abnormal serum phosphate levels (Grade 3 and above)
- Has a clinically apparent finding on speculum pelvic examination (observed by study staff) involving deep epithelial disruption. Otherwise eligible participants with speculum pelvic examination findings involving deep epithelial disruption may proceed with enrolment after the findings have resolved and the inclusion/exclusion are met.
- Received previously or receiving an experimental HIV vaccine
- Currently participating in another HIV prevention intervention study or participation in any other clinical trial with a biomedical intervention in the last six months
- Has current STI symptoms and/or other reproductive tract infection requiring treatment, as assessed by study staff. Otherwise eligible participants diagnosed during screening with infection(s) requiring treatment may be enrolled provided that treatment has been completed.
- Any clinical evidence of untreated cervical abnormalities
- Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tenofovir 1% vaginal gel
Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
|
Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5.
Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
|
Placebo Comparator: Universal placebo gel
Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
|
The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide.
Each applicator contains approximately 4ml of placebo gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness
Time Frame: 30 months
|
Incidence of HIV-1 infection: HIV incidence will be determine by detection of HIV antibodies using two HIV rapid tests (of which one will be FDA approved) according to algorithm in protocol.
One of the rapid tests will detect both HIV-1 and HIV-2; the other will be specific for HIV-1.
All endpoints will be reviewed by an expert committee (the Endpoint Adjudication Committee).
In carrying out this review, the Committee will use guidelines prepared by the protocol committee for this purpose and recorded in the Manual of Procedures
|
30 months
|
Safety
Time Frame: 30 months
|
Grade 2, 3, and 4 clinical and laboratory adverse events as defined by the DAIDS toxicity table
|
30 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of HSV-2 infection
Time Frame: 30 months
|
HSV-2 status will be established at enrollment according to a testing algorithm in the protocol.
At product discontinuation samples of all those that were HSV-2 seronegative at enrollment will be tested.
To identify and confirm incident HSV-2 infections and the timing of these infections, blood samples that were stored will be tested to determine the earliest equivocal or positive result.
These samples will be then be tested by HSV Western blot.
Samples positive on HSV Western blot will be deemed to be incident HSV-2 infections.
|
30 months
|
Pregnancy
Time Frame: 30 months
|
Incidence of pregnancy loss, prematurity, low birth weight, and major and minor congenital anomalies will be determined
|
30 months
|
Gel and condom use
Time Frame: 30 months
|
30 months
|
|
HIV-1 incidence after product withdrawal
Time Frame: 3 months after product withdrawal
|
HIV testing will be conducted 3 months after product discontinuation and if HIV positive, the last stored sample will be tested to ascertain timing of infection and viral tenofovir resistance testing will be performed
|
3 months after product withdrawal
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Helen Rees, Prof, University of Witwatersrand, South Africa
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Herpesviridae Infections
- Slow Virus Diseases
- HIV Infections
- Infections
- Acquired Immunodeficiency Syndrome
- Herpes Simplex
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
Other Study ID Numbers
- FACTS 001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Prevention
-
Prof Mags BeksinskaCompletedHIV Prevention | Pregnancy PreventionSouth Africa
-
Yale UniversityCompletedHIV Prevention | STI PreventionUnited States
-
Centers for Disease Control and PreventionUniversity of Minnesota; The Fenway Institute; AIDS Action Committee of Massachusetts and other collaboratorsCompletedHIV Prevention | STD PreventionUnited States
-
International Partnership for Microbicides, Inc.CompletedHIV PreventionSouth Africa, Uganda
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompleted
-
Fenway Community HealthCompleted
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... and other collaboratorsCompletedHIV PreventionUnited States
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUganda, South Africa, Zimbabwe
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompleted
-
Orion Biotechnology Polska Sp. z o.o.Scope International AGCompleted
Clinical Trials on Tenofovir gel
-
University of WashingtonGilead Sciences; CONRADCompletedHerpes Simplex Type IIUnited States
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); National Institute...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Completed
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
National Institute of Allergy and Infectious Diseases...Withdrawn
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedHIVUnited States, South Africa, Peru, Puerto Rico, Thailand
-
Ian McGowanNational Institute of Allergy and Infectious Diseases (NIAID); CONRADCompleted
-
CONRADEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV Negative | High Risk MSM | 18-30 Years of AgeUnited States, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...Completed